Category: PSA Screening

Less than a third of men with a PSA result in the "gray zone" of 4–10 actually have prostate cancer. Yet for years, that number alone sent patients straight to biopsy. Today, mpMRI offers a smarter first step and a newly FDA-approved blood test called IsoPSA may be the safety net for cases MRI can't fully resolve. keep reading

Traditional PSA screening can lead to overdetection and unnecessary biopsies due to its lack of specificity for prostate cancer. New research highlights biparametric MRI as a promising, quicker, and potentially more accurate first-line screening tool. keep reading

Can a cancer diagnosis bring a sense of relief? For men with prostate cancer caught at Grade Group 1, emerging research and expert protocols suggest that aggressive treatments can often be avoided. Active surveillance, targeted focal therapies, and more precise diagnostic tools are helping many choose paths that spare quality of life. keep reading

Australia is rethinking prostate cancer screening, proposing annual PSA testing, earlier screenings for high-risk men, and the integration of mpMRI to improve detection. The reforms aim to address past guideline shortcomings and reduce late-stage diagnoses. keep reading

Emerging research reveals that early PSA after radiation and androgen deprivation therapy can help predict prostate cancer outcomes. Meanwhile, a new genomic test is showing potential for identifying which patients face higher risk of long-term urinary side effects. keep reading

Delaying or skipping PSA testing can have life-threatening consequences. New data confirms more men are being diagnosed with advanced prostate cancer when it’s too late for local treatment. Annual PSA checks can make all the difference. keep reading

A British clinical trial and new Italian study highlight how pairing MRI with PSA density could change prostate cancer detection. By refining who needs biopsy, this method offers earlier diagnosis of significant cancers while avoiding unnecessary procedures. keep reading

Is PSA testing about to lose its crown? With ultrafast MRI proving faster, more accurate, and less anxiety-inducing, researchers say the balance may be tipping toward MRI as the new “king” of prostate cancer screening. keep reading

Today’s multiparametric MRI (mpMRI) is better than ever. When a patient’s PSA blood test raises suspicion of prostate cancer (PCa), mpMRI determines if a targeted biopsy is needed. It does this by making significant lesions visible prior to an invasive biopsy. Significant means Gleason 3+4 or greater, also characterized as Grade Group 2 or greater. keep reading

The use of 2 parameters of imaging sequences is called biparametric MRI (bpMRI) – and new research shows it could make MRI widely available as a better screening tool than the PSA test which can lead to overdiagnosis and overtreatment. Now there’s an exciting boost to the speed and accuracy of bpMRI: Deep Learning (DL), a branch of Artificial Intelligence (AI). keep reading